Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy
about
Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsyNew models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients.Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification.Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients.Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapyRole of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.Accurate staging of axillary lymph nodes from breast cancer patients using a novel molecular methodWhich patients need an axillary clearance after sentinel node biopsy?Prediction of non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastases: evaluation of the tenon scoreOne-Step Nucleic Acid Amplification in Breast Cancer Sentinel Lymph Node: A Single Institutional Experience and a Short Review.Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel nodeThe microanatomic location of metastatic breast cancer in sentinel lymph nodes predicts nonsentinel lymph node involvement.Sentinel lymph node biopsy for breast cancer: current controversies.Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.Is axillary clearance the standard of care for breast cancer patients with sentinel node involvement?Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer.Quantitation of the Regional Lymph Node Metastatic Burden and Prognosis in Malignant Mammary Tumors of Dogs.Significance and management of micrometastases in patients with breast cancer.Axillary Lymph Node Status in Early-Stage Breast Cancer Patients with Sentinel Node Micrometastases (0.2-2 mm).Current molecular diagnostics of breast cancer and the potential incorporation of microRNAIntraoperative diagnosis of sentinel lymph node metastases in breast cancer treatment with one-step nucleic acid amplification assay (OSNA)Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.Clinical significance of sentinel lymph node isolated tumour cells in breast cancer.One-step nucleic acid amplification assay (OSNA) for sentinel lymph node biopsy.Three models for predicting the risk of non-sentinel lymph node metastasis in Japanese breast cancer patients.Consensus on the regional lymph nodes irradiation in breast cancer.Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.Validation and comparison of models to predict non-sentinel lymph node metastasis in breast cancer patients.Regional Disease Control in Selected Patients with Sentinel Lymph Node Involvement and Omission of Axillary Lymph Node Dissection.Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.Development of a Nomogram to Predict N2 or N3 Stage in T1-2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy.Outcome of patients with ductal carcinoma in situ and sentinel node biopsy.Evaluation of the Metasin assay for intraoperative assessment of sentinel lymph node metastases in breast cancer.Comparison of the Indocyanine Green Fluorescence and Blue Dye Methods for the Detection of Sentinel Lymph Nodes in Early-stage Breast Cancer: A Reply.Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group.Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?The appropriate axillary procedure after a positive sentinel node in breast cancer patients: the "Hôpital Tenon" score revisited. A two-institution study.Peritumoral apparent diffusion coefficients for prediction of lymphovascular invasion in clinically node-negative invasive breast cancer.Precise pathologic examination decreases the false-negative rate of sentinel lymph node biopsy in gastric cancer.Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node.
P2860
Q26747688-04831C5F-EB5A-4367-9E06-B95B91F228B8Q33322239-9FA8A773-94F3-465E-B81B-7F8CF92488B6Q34443092-694B1419-1540-430E-BDCE-F6D0F4D8AF19Q35090900-B3084417-36A9-409D-AD3F-308C687DD307Q35194725-51F40534-DA07-4CAB-BFB2-06EF28EF60AAQ35221922-FC04BF3B-DF60-4C0E-97EA-99919B2A3797Q35527120-FDA12569-E22F-4BA4-84A7-1363D9064820Q35684387-E041B8CF-BFA9-4101-8FB3-E1984009E22EQ35739425-11B11606-1FEF-49C3-BA83-4272E4FB332EQ35747268-B345AF8A-B900-4FEC-8775-1FFFD3830145Q35821092-396842CD-C58E-4FA7-9522-79DE61B56586Q36514431-7468FFB4-5489-425C-B023-ED9B94EEF2AAQ36588406-DFDDC7FB-8DA9-43C7-A148-1269A522C50DQ36598695-0A339D5B-C4EB-4D14-920E-7F655C25BD1EQ36616508-78583118-04A2-4E1B-86D2-E27D1943104FQ36636663-0EAD19ED-7074-418B-90D7-ECCFBA9C8F22Q36873505-ACD34911-7EB7-4BAF-A0CB-3A3B6435F322Q36974710-73E75118-7492-44C1-AB29-160186F4688AQ37058009-914F2C2F-1898-4DA8-A3E3-2C76ED762E12Q37378012-8509C903-D3A9-45EC-BAE8-0A025F00F6A8Q37412668-8E2307AF-99FC-41DA-9F9F-D56A0D94122CQ37669469-A6745CA3-6EBB-417A-B47A-8C29631BC4B4Q37860190-ACCDD089-2395-4C16-9C55-2B55A8B1F7B8Q38033118-C029EE75-B207-45E4-8BDF-744CB56FFA9EQ38073188-87D1DFB7-4959-4CA2-95AC-8BA3FC2A238CQ38091991-4AB14A0F-BA03-417C-A144-EBB35D3588D5Q38821703-E791F100-DB9C-4BCD-A196-08A296AFD286Q39690161-FD825A72-D37B-4C4F-B37D-C2590B9B4594Q41484688-A4B54464-3A8F-446C-A09F-003D7CDAA0BEQ42026408-26B51633-8FB7-4A16-BA14-DAB34D3E17EEQ42153163-CF738CEB-E757-4C1A-8A6D-2BB1BEBFC95DQ44530128-D6532B41-8EBF-4889-A0D0-EDB0960C66C2Q47744976-1367D89F-3EB6-4E34-8479-508A5404F101Q50147600-32553E8E-61EE-4060-8B04-01F09A8B581BQ50546744-7169E248-974D-463F-AC7E-A32E6FCE1D63Q52639255-B6A4E14F-6706-4054-B991-81802847E71AQ53163054-AC3AD360-B5DD-414A-91BB-6EB7A45C98B1Q53221975-F34BBE54-4244-42A5-BE5C-50FA8EB6B5A5Q53403280-C101C5FE-A71A-474A-8010-FD03CDF359CBQ54549875-F14730D0-4CF1-419E-85E3-BAF16595D246
P2860
Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy
description
im Februar 2005 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2005
@uk
name
Predicting the risk for additi ...... ive sentinel lymph node biopsy
@en
Predicting the risk for additi ...... ive sentinel lymph node biopsy
@nl
type
label
Predicting the risk for additi ...... ive sentinel lymph node biopsy
@en
Predicting the risk for additi ...... ive sentinel lymph node biopsy
@nl
prefLabel
Predicting the risk for additi ...... ive sentinel lymph node biopsy
@en
Predicting the risk for additi ...... ive sentinel lymph node biopsy
@nl
P2093
P2860
P50
P1433
P1476
Predicting the risk for additi ...... ive sentinel lymph node biopsy
@en
P2093
Giancarlo Pruneri
Giovanni Mazzarol
Stefano Valentini
Stefano Zurrida
Viviana Galimberti
P2860
P304
P356
10.1097/01.SLA.0000150255.30665.52
P407
P577
2005-02-01T00:00:00Z